Last reviewed · How we verify
castration resistant prostate cancer crpc
Approved treatments
Clinical guidelines
- FDA label — 1L|2L|3L+|any
XTANDI is indicated for the treatment of patients with castration-resistant prostate cancer. - FDA label — 1L
XTANDI is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. - FDA label — 1L
XTANDI is indicated for the treatment of patients with non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. - FDA label — 1L
XTANDI is indicated for the treatment of patients with castration-resistant prostate cancer. - FDA label — 1L
XTANDI is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. - FDA label — 1L
XTANDI is indicated for the treatment of patients with non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- castration resistant prostate cancer crpc patent landscape — cliff calendar, originator estates, attackable patents
- castration resistant prostate cancer crpc treatment landscape brief
- castration resistant prostate cancer crpc treatment updates RSS
Frequently asked questions about castration resistant prostate cancer crpc
What are the treatment guidelines for castration resistant prostate cancer crpc?
FDA label publishes guidelines for castration resistant prostate cancer crpc. 6 guideline references tracked.
Related
- Treatment landscape: castration resistant prostate cancer crpc patent cliff · castration resistant prostate cancer crpc CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing